Inovio Pharmaceuticals, Inc. — FY2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. The filing is an annual report, not a standalone fourth-quarter filing; Q4 figures below are unaudited. Inovio is a clinical-stage biotechnology company developing DNA-based immunotherapies and vaccines with its CELLECTRA delivery devices. It had no approved products or product-sale revenue.
Financial performance and liquidity
| Metric | FY2018 | FY2017 |
|---|---|---|
| Total revenue | $30.5 million | $42.2 million |
| Operating expenses | $124.6 million | $125.9 million |
| Operating loss | $94.1 million | $83.6 million |
| Net loss | $97.0 million | $88.2 million |
| Basic net loss per share | $1.05 | $1.08 |
| Cash and short-term investments at year-end | $81.2 million | $127.4 million |
| Working capital at year-end | $52.5 million | $103.0 million |
| Net cash used in operating activities | $73.6 million | $63.2 million |
Research and development expense was $95.3 million and general and administrative expense was $29.3 million. In 2018, $9.5 million of grant funding was presented as a reduction of R&D expense rather than grant revenue following adoption of new accounting guidance; on a comparable presentation before that change, 2018 revenue would have been $40.0 million and R&D expense $104.7 million. The company reported no product-sales revenue, so product margins are not applicable.
At year-end, total assets were $131.1 million, total liabilities $44.1 million, and stockholders’ equity $87.0 million. The filing reports no material long-term debt at December 31, 2018. It does disclose $35.7 million of operating lease obligations, including $3.8 million due within one year. Subsequent to year-end, Inovio issued $78.5 million principal amount of 6.50% convertible senior notes due 2024, receiving estimated net proceeds of $75.8 million.
Q4 2018: Revenue was $2.5 million versus $8.8 million in Q4 2017; operating loss was $29.5 million versus $22.9 million; net loss was $33.0 million versus $21.5 million. Q4 2018 basic and diluted loss per share were each $0.34.
Material changes versus prior periods
- Reported FY2018 revenue fell 28% year over year, principally reflecting lower grant revenue presentation and changes in collaboration revenue. Under the new grant accounting treatment, $9.5 million was recorded as an R&D expense reduction rather than revenue.
- Collaborative revenue was $30.3 million, including a $23.0 million ApolloBio upfront license payment. ApolloBio represented 75% of total reported revenue; AstraZeneca represented 23%.
- Net loss increased 10% to $97.0 million, despite slightly lower reported operating expenses; operating loss increased 12%. Operating cash use also increased by $10.3 million.
- Cash and short-term investments declined $46.2 million, while the company raised $29.2 million net through common-stock sales and received $19.4 million net from ApolloBio after specified taxes.
- Shares outstanding increased from 90.4 million at year-end 2017 to 97.2 million at year-end 2018, reflecting equity issuance and exercises. The 2018 ATM program generated $27.7 million net proceeds.
Outlook, commentary, and key risks
- Management expects substantial operating losses to continue and states that no product revenue is expected for at least several years. It said year-end cash and investments, together with the 2019 note proceeds, were sufficient to support operations for at least 12 months from issuance of the financial statements; additional capital will be needed to fund development.
- Inovio’s lead candidate VGX-3100 was in Phase 3 trials for HPV-related cervical precancer. If the REVEAL studies are positive, the company was targeting a U.S. biologics license application by the end of 2021. Interim results from its Phase 2 vulvar trial were anticipated in the second half of 2019.
- Other programs included clinical studies in HPV-related cancers, bladder cancer, glioblastoma, hepatitis, HIV, and infectious diseases. These candidates remain investigational; early immune-response or preclinical findings do not establish clinical benefit or approval.
- Funding and revenue are exposed to collaboration and grant timing, milestone achievement, and concentration in a small number of counterparties. Clinical failure or delay, regulatory requirements, manufacturing issues, competition, and inability to raise capital on acceptable terms could materially harm operations.
- The company reported an accumulated deficit of $620.4 million and stated it may never achieve profitability. Future equity financing could dilute shareholders; the 2019 convertible notes carry 6.50% interest and may also create cash-settlement or dilution exposure upon conversion.
- Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2018. The auditor issued an unqualified opinion on the financial statements.
Investor verification priorities
- Track REVEAL Phase 3 enrollment, endpoints, results, regulatory discussions, and the timing and feasibility of the targeted VGX-3100 filing.
- Reconcile revenue trends on a comparable basis after the 2018 grant-accounting change; distinguish collaboration milestones and upfront payments from recurring revenue.
- Verify cash burn, investment balances, financing capacity, and runway against clinical spending; assess the terms, conversion provisions, interest cost, and potential dilution of the 2019 notes.
- Monitor dependence on ApolloBio, AstraZeneca, government grants, and other collaborators, including milestone conditions, termination rights, and funding commitments.
- Assess the clinical evidence and safety, regulatory, manufacturing, and commercialization risks across the pipeline; all candidates remain unapproved.